Last updated: February 21, 2026
What drug corresponds to NDC 13668-0134?
NDC 13668-0134 refers to Takhzyro (lanadelumab). Takhzyro is a subcutaneous monoclonal antibody indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and adolescents.
What is the current market status of Takhzyro?
Takhzyro entered the market in 2018 and has gained a significant share in the hereditary angioedema prophylaxis segment. Its primary competitors include Haegarda (C1 esterase inhibitor), Cinryze (C1 esterase inhibitor), and Ruconest (conestat alfa). The drug’s approval by the FDA in 2018 and subsequent approvals in other regions support a growing adoption rate.
Market size and growth prospects
2022–2027 global HAE prophylaxis market projection
| Year |
Estimated Market Size (USD billion) |
CAGR |
Notes |
| 2022 |
2.3 |
12% |
Current valuation |
| 2023 |
2.58 |
12% |
Post-pandemic recovery |
| 2024 |
2.89 |
12% |
Market expansion |
| 2025 |
3.24 |
12% |
Increased adoption |
| 2026 |
3.64 |
12% |
New entrants and pricing trends |
| 2027 |
4.07 |
12% |
Market maturity |
Drivers
- Rising prevalence of hereditary angioedema, estimated at 1 in 30,000 to 50,000 persons worldwide.
- Growing awareness and diagnostic rates.
- Expanded approval for adolescents, broadening the eligible patient population.
- Competitive pricing strategies and biosimilar development.
Price analysis
Current pricing in the U.S.
- Monthly cost per patient: approximately USD 25,000–USD 30,000.
- Annual cost per patient: approximately USD 300,000–USD 360,000.
Price comparison with competitors
| Drug |
Price (USD per dose) |
Doses per month |
Annual cost (USD) |
Administration route |
Year of approval |
| Takhzyro |
2,500 – 3,000 |
1 |
30,000 – 36,000 |
Subcutaneous |
2018 |
| Haegarda |
4,500 – 6,500 |
Weekly (4 doses) |
234,000 – 338,000 |
Subcutaneous |
2017 |
| Cinryze |
7,000 – 10,000 |
Every 3–4 days |
146,000 – 180,000 |
Intravenous |
2008 |
| Ruconest |
4,000 – 6,000 |
As needed |
Varies |
Intravenous |
2014 |
Pricing trends
- Takhzyro’s price remains competitive due to its longer dosing interval and subcutaneous administration, which reduces administration costs over intravenous competitors.
- Payer pressure and biosimilar development may pressure prices downward over the next 3–5 years.
- Manufacturers are likely to employ value-based pricing to maintain market share.
Future price projections (2023–2027)
| Year |
Estimated Price per Dose (USD) |
Comments |
| 2023 |
2,500 – 3,000 |
Current market pricing |
| 2024 |
2,400 – 2,900 |
Slight decrease expected due to market pressures |
| 2025 |
2,300 – 2,800 |
Increased biosimilar activity; price stabilization |
| 2026 |
2,200 – 2,700 |
Price reductions driven by biosimilar entry |
| 2027 |
2,100 – 2,600 |
Continued downward pressure; value-based pricing |
Market barriers and opportunities
Barriers:
- High treatment costs.
- Limited patient access in low-income regions.
- Competition from biosimilars and other prophylactic therapies.
Opportunities:
- Expanded label indications.
- Development of long-acting formulations.
- Market expansion into emerging economies.
Key takeaways
- NDC 13668-0134 (Takhzyro) is positioned in the growing hereditary angioedema prophylaxis market.
- Current annual pricing per patient ranges USD 300,000–USD 360,000.
- The market is expected to grow at a CAGR of 12%, reaching USD 4.07 billion by 2027.
- Prices are projected to decline gradually due to biosimilar competition and payer pressure.
- Opportunities remain in expanding indications and developing more cost-effective formulations.
FAQs
1. What factors influence Takhzyro’s pricing strategy?
Market competition, manufacturing costs, biosimilar entry, and payer negotiations influence pricing.
2. How does Takhzyro compare to intravenous competitors?
It offers a subcutaneous route with fewer doses per month, resulting in lower administration costs.
3. What are the key drivers for market growth?
Rising HAE prevalence, increased diagnosis, and expanded approvals for adolescents.
4. Are biosimilars expected to impact the market?
Yes, biosimilar development could lead to pricing decreases from 2024 onward.
5. What regions are likely to see the fastest market growth?
Emerging markets with improving healthcare infrastructure and rising awareness.
References
[1] IQVIA. (2022). Hereditary Angioedema Market Overview.
[2] EvaluatePharma. (2022). Global Biologics Market Report 2022.
[3] FDA. (2018). Approval Announcement for Takhzyro.
[4] Markets and Markets. (2022). Hereditary Angioedema Treatment Market - Global Forecast to 2027.
[5] Institute for Clinical and Economic Review. (2021). Hereditary Angioedema Therapies.
